Asthma control · adults with asthma not well controlled on ICS
1 finding from 1 review
Any adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in any adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring a course of OCSa 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
AQLQ score (Scale 1 to 7, where 1 = severely impaired and 7 = no impairment) · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
SAEs · adults with asthma
ICS + LAMA add‐on showed no clear difference in SAEs (all cause) compared with ICS dose increase (low certainty).
1 finding from 1 review
Exacerbations needing hospitalisation · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring hospitalisation 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
Exacerbations leading to ED visits · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring ED visit 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
FEV1 · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Exacerbations (OCS) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in exacerbations (OCS) compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
AQLQ total 1 = severely impaired; 7 = not impaired at all 22 weeks · adults with asthma not well controlled on ICS
1 finding from 1 review
Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Hospital admission (exacerbation) · adults with asthma not well controlled on ICS
It is very uncertain whether long‐acting muscarinic antagonists (LAMA) add‐on changes exacerbations (hospital) compared with long‐acting beta2‐agonists (LABA) add‐on (very low certainty).
1 finding from 1 review
FEV1 · adults with asthma not well controlled on ICS
1 finding from 1 review
ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma not well controlled on ICS
1 finding from 1 review
Adverse events (all) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).
1 finding from 1 review
Change from baseline in morning PEFR (L/min) Duration of trials: 8 to 13 weeks · patients with chronic asthma
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · patients with chronic asthma
1 finding from 1 review
Rescue‐free days: % change from baseline · patients with chronic asthma
1 finding from 1 review
Use of rescue medication · patients with chronic asthma
1 finding from 1 review